Screening people with memory problems for eligibility for Alzheimer treatment
Tests digital memory tools and blood markers to screen for Alzheimer treatment.
Plain-language title generated from the registry record
Registry title: Screening for Anti-amyloid Treatment Eligibility Using Digital Cognition and Blood-based Biomarkers
Key facts
- Where
- Greenfield Park, CanadaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 55 to 90 referred to the MoCA Clinic with memory or thinking problems or complaints, who have a study partner who knows them well.
- Age
- 55 to 90 years
- Sex
- All sexes can join.
- Disease stage
- People with cognitive impairment or cognitive complaints, referred to the MoCA Clinic (new patients, or existing patients last seen more than 1 year ago).
- Earlier treatment
- People already enrolled in a clinical trial for Alzheimer's disease cannot join.
Main reasons for not taking part
- Another established diagnosis (other than Alzheimer's disease) that causes the cognitive impairment, such as substance abuse, cerebrovascular conditions, Lewy body dementia, fronto-temporal dementia or recent head trauma
- Gave blood (1 unit) within 1 month before screening
- Cannot complete the essential parts of the study, for example because of visual impairment, severe kidney disease or ongoing kidney treatment
- Already enrolled in a clinical trial for Alzheimer's disease
- No study partner who has frequent contact and can give information by phone and come to one in-person visit
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 55 and 90 years old?
Source: NCT07041450, who can take part
Where in Canada
- MoCA Clinic and InstituteGreenfield Park, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- MoCA Clinic and Institute
- Trial code
- NCT07041450
- Record updated
- 1 July 2025
- Original description
This study evaluates a diagnostic screening solution for Alzheimer's disease (AD) using digital cognitive assessments and blood-based biomarkers. The aim is to reduce time-to-treatment for patients who may benefit from disease-modifying therapy (DMT). The study involves 500 patients referred to the MoCA Clinic in Montreal. Clinical stages will be assessed using digital tools from MoCA Test Inc. (MoCA Cognition), and biological stages via blood biomarkers. Data collected includes demographics, cognitive scores, health questionnaires, biomarker levels, and neurologist-determined eligibility for DMT. The study will result in an algorithm to support diagnostic triage and estimate the efficiency and equity of a fast-track diagnostic pathway. Exploratory endpoints include validation of self-administered digital tools, health-economic estimates, and predictors of cognitive decline.Read full original descriptionShow less
A Cohort Study on Screening for Anti-amyloid Treatment Eligibility Using Digital Cognition and Blood-based Biomarkers
This study evaluates a diagnostic screening solution for Alzheimer's disease (AD) using digital cognitive assessments and blood-based biomarkers. The aim is to reduce time-to-treatment for patients who may benefit from disease-modifying therapy (DMT). The study involves 500 patients referred to the MoCA Clinic in Montreal. Clinical stages will be assessed using digital tools from MoCA Test Inc. (MoCA Cognition), and biological stages via blood biomarkers. Data collected includes demographics, cognitive scores, health questionnaires, biomarker levels, and neurologist-determined eligibility for DMT. The study will result in an algorithm to support diagnostic triage and estimate the efficiency and equity of a fast-track diagnostic pathway. Exploratory endpoints include validation of self-administered digital tools, health-economic estimates, and predictors of cognitive decline.
Inclusion: Must be referred to the MoCA Clinic; including both new patients and existing patients who have been seen >1 year ago; Present with cognitive impairment or cognitive complaints; Must have the ability to understand the purpose and risk of the Study and provide informed consent; Must have an identified study partner (informant/care partner), who has frequent and sufficient contact with the participant to be able to provide accurate information about the participant's cognitive and functional abilities. The study partner must be available by phone to provide information to the study staff about the participant and agrees to attend one in-person visit at the MoCA Clinic which requires partner input. The study partner should be available for the duration of the study.
Exclusion: Blood donation (1 unit) within 1 month prior to Study screening; An established diagnosis (other than AD), that is a cause for a candidate's cognitive impairment (e.g. substance abuse, cerebrovascular conditions, Lewy body dementia, fronto-temporal dementia, recent head trauma); Inability to comply with requirements to complete essential components of the Study (e.g. visual impairment, severe kidney disease or ongoing kidney treatment); Patients already enrolled in any clinical trial for AD at time of Study screening; Other unspecified reasons that, in the opinion of the Principal Investigator, or MoCA Clinic and Institute, make the candidate unsuitable for enrolment.